Welcome to Dash, Sylvia Lustig, as the Associate Director of Project Delivery! Sylvia brings a background in chemical engineering, fermentation, and cell culture, along with 10 years of synthetic biology R&D experience. From flavors and fragrances to pharmaceuticals, she’s an expert in improving lab workflow efficiency and project planning. She knows firsthand how to optimize the processes that help get results out the door. She’s got the mindset and drive to keep everything running smoothly so you get high-quality data back quickly. We’re so glad to have you!
About us
At Dash Bio, we're revolutionizing bioanalysis to expedite drug development. By leveraging robotics and modern software, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average, scaling seamlessly from preclinical through late-stage clinical studies. While drug discovery has been revolutionized with AI and breakthrough modalities, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market while improving quality of results. Meet Our Leadership Team: Dave Johnson, CEO: Former Chief Data and AI Officer at Moderna. Ander Tallett, COO: Led Enterprise Systems at Moderna and Resilience. Ely Porter, CSO: Co-founder and CTO of Rootpath. Together, we're crafting a future where bioanalysis is intuitive, data flows effortlessly, and drugs reach the market faster than ever before. Join us on this journey. Learn more at dash.bio
- Website
-
https://dash.bio
External link for Dash Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2024
Employees at Dash Bio
View 46 employees at Dash Bio
or
Locations
-
Primary
Get directions
56 Broad St
Boston, Massachusetts 02109, US
Updates
-
Welcome to Dash, Andrés Bretón, as a Principal Software Engineer! Andrés has spent over 10 years at the intersection of software engineering and life sciences. He specializes in platform engineering and developer experience, and builds the infrastructure, pipelines, and internal tools that let teams move fast, operate reliably, and self-serve with confidence. What stands out is how Andrés brings the human side of software engineering into system and tool design: developer experience is the core platform responsibility, built by understanding how engineers work. We’re excited to have you with us! 🚀 💻
-
-
Dash recently celebrated our $30M Series A at Fenway, and made a brief appearance on the Jumbotron! This milestone is the culmination of our team's hard work and the support of our investors and customers who believed in us from the start. Thank you for being part of what we're building. The next chapter is about expanding capacity, bringing on more assays, and helping more teams get to answers faster. ...and Go Sox! ⚾️
-
Welcome to Dash, Sofia Simonoff, as an Associate Software Engineer! Sofia is a full-stack software engineer with experience building internal tools and workflows. From fintech to biotech, she’s worked in environments that demand both technical depth and the ability to work closely with the people using what she builds. Sofia cares about building reliable software that solves complex problems and delivers real-world impact, backed by data you can trust. That kind of thinking is exactly what bioanalysis needs. We’re so glad to have you! 🚀 💻
-
-
We’re excited to share that Benjamin Trapp, Principal Automation Engineer, will be joining the panel “Lab Software in the Agentic Era” at LRIG New England’s upcoming event on laboratory software, informatics, and infrastructure! He’ll share his insights on custom LIMS and automated bioanalytical workflows. Where: 35 Landsdowne St, Cambridge, MA When: 5:30 - 8:00 PM If you’re building or thinking about the future of lab informatics, this is a good event to catch! Register here: https://lnkd.in/gg7FWge7
-
-
"The more successful AI becomes at drug discovery, the more urgently we need to reinvent drug development." Dave Johnson
The more successful AI becomes at drug discovery, the more urgently we need to reinvent drug development. A new Nature Reviews Drug Discovery paper, covered in Axios today, describes the evidence of AI's clinically relevant impact as "disappointingly limited." I'm incredibly optimistic about AI's potential, but this is an important reminder that better discovery alone won't get more medicines to patients. A promising drug candidate is still a hypothesis. Developing it requires generating evidence about whether it works, whether it's safe, and how it behaves in the body. If we dramatically expand our ability to generate candidates without improving our ability to evaluate them, we risk creating a larger backlog rather than a more productive industry. The labs, workflows, and business models that generate that evidence deserve the same level of reinvention as the algorithms generating candidates. We need to make it faster and less expensive to answer development questions, while maintaining the rigor those decisions require. At Dash Bio, that's how we think about the role of bioanalysis. The value isn't simply in running an assay faster. It's in getting reliable data into a sponsor's hands sooner so they can decide what to advance, what to change, or what to stop. AI's impact will ultimately be measured in better medicines reaching patients. Realizing that potential requires us to be just as ambitious about development as we are about discovery. https://lnkd.in/gDxDsApV
-
Welcome to Dash, Nathaniel White, as an Associate Software Engineer! Nathaniel joins us with a multidisciplinary background in Computer Science, Statistics, Physics, and Chemistry. He’s spent his career developing a deep understanding of both the natural sciences and the mathematics behind software. Nathaniel has a unique talent for building tools that truly understand bioanalysis. We’re excited to have you on the team! 🚀 💻
-
-
The Dash Bio team is excited to be at the Applied Pharmaceutical Analysis (APA) Conference in Boston! Stop by our booth to talk bioanalysis, or join us at Lamplighter Brewing (CX) tonight (9/15) evening for a casual get-together with industry peers after the conference. Register for the event here: https://luma.com/1anhb2bq Where: 110 N. First St, Cambridge, MA When: September 15th, 6:00 - 8:00 PM #APA2026 #Bioanalysis #DPMK #ADME
-
-
Lots of people build robots to move things. We use robots to turn biology into data, and we deeply appreciate that it landed us a Top 25 spot from Business Insider for the Most Promising Robotics Startups. A lab robot handling clinical trial samples has to be perfect every time, documented every time, and auditable under GLP. To run sponsor samples, you also have to be flexible, each assay unique. That combo is why bioanalysis stayed manual for decades while every other industry automated. We integrated the automation, software, and quality system as one platform. The result: assay results in days, prices published at dash.bio/pricing, and a market that still runs on paper records getting its first real infrastructure. The most valuable thing a robot can move is not a pallet. It is a drug program. Thank you to Cybernetix Ventures for the nomination! https://lnkd.in/gxx9Ewdt
-
The bioanalysis community spends its days on some of the hardest problems in drug development. We think that deserves a round! Join us for Bioanalysis & Brews at Mighty Squirrel Taproom & Kitchen in Waltham on August 18th! Drinks and apps are on us. Come connect with fellow scientists and drug developers from across the Boston area. 🗓️ Register here: http://luma.com/tdl2uwlt